Coles is Chief Executive Officer and Chairperson of Cerevel Therapeutics since 2019. Since 2014, he is also Co-founder and Chairperson of Yumanity Therapeutics LLC, where he was instrumental in establishing and advancing a drug discovery platform based on live cell modeling that has resulted in three novel drug candidates for the potential treatment of Parkinson’s disease, related synuclein disorders, and Amyotrophic Lateral Sclerosis (Lou Gehrig’s disease). Just prior, Dr. Coles served as the chairman and chief executive officer of TRATE Enterprises LLC, a privately held company. Dr. Coles served as President, Chief Executive Officer, and Chairman of the Board of Onyx Pharmaceuticals, Inc., which was acquired by Amgen in 2013, having served as its President and Chief Executive Officer, and a member of its board of directors in 2008–12. Under his leadership, Onyx introduced two new innovative cancer medicines to patients and established the company’s international presence outside of the U.S.
Dr. Coles currently serves as a member of the board of directors of McKesson Corporation and Regeneron Pharmaceuticals. He was vice chair of the board of trustees of Johns Hopkins University and a trustee of Johns Hopkins Medicine. He is a trustee of the Metropolitan Museum of Art, a board member of the Council on Foreign Relations, and a member of the Harvard Medical School Board of Fellows. Dr. Coles also serves as a member of the Council of the Smithsonian’s National Museum of African American History and Culture and as co-chair of the Black Economic Alliance.